Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the drug ...
Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...
TL;DR A production-ready, reproducible pipeline for skin-disease image classification with a multilayer router: L1 (Normal vs Abnormal) → L2 (8 abnormal classes) → optional L3 (Subclass) under Eczema ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results